TERUMO CORP UNSP/ADR (TRUMY)
TRUMY moved a median of +0.14% 30 minutes after news, and +0.10% by the close. How TRUMY actually reacts to news — the realized, point-in-time move the market made, measured across 43 labeled events over the last three years with zero look-ahead.
TRUMY’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 32% | 41 |
| 30-min | +0.14% | 61% | 43 |
| 60-min | +0.04% | 51% | 43 |
| to close | +0.10% | 54% | 43 |
| Middle 50% of TRUMY reactions | -0.17% to +2.85% |
|---|---|
| Median reaction (30-min) | +0.14% |
| Measured reactions | 43 |
Half of all TERUMO CORP UNSP/ADR news events land between -0.17% and +2.85% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when TRUMY moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to TRUMY's baseline. Nothing else.
Recent TRUMY events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| NICE Supports Routine NHS Funding and Access to Ex-Situ Machine Perfusion in a Major Step Forward for Liver Transplantation | Press release | GlobeNewswire | -0.43% | -0.18% | |
| Terumo Interventional Systems Announces First Procedure Using Its OPUSWAVE® Dual Sensor Imaging System in the United States | Press release | PR Newswire | +0.00% | +0.04% | |
| OrganOx Announces Appointment of Naoya Iwata as CEO & President | Press release | GlobeNewswire | +0.00% | +0.00% | |
| StafaCT Launches a Pioneering Direct Spectra Optia Integration at Leading Global Apheresis, Cell Therapy and Transplant Center | Press release | PR Web | — | -0.26% | |
| Terumo Blood and Cell Technologies introduces APAC C> Ecosystem Blueprint | Press release | PR Newswire | +1.72% | +1.23% | |
| Q-Sera announces the first launch of blood collection tubes using its patented Rapclot technology in Japan, opening opportunities for additional global partnerships | Press release | GlobeNewswire | +0.00% | -0.23% | |
| Terumo Launches SurTract™ Safety Syringe in the United States, Powered by Roncadelle Operations' SafeR® Passive Safety Technology | Press release | PR Newswire | -0.07% | +0.21% | |
| OrganOx Completes Acquisition by Terumo Corporation to Advance the Future of Organ Transplantation | Press release | GlobeNewswire | +4.25% | +3.56% | |
| Geisinger and Terumo Neuro Advance Stroke Education and Neurovascular Innovation in Recognition of World Stroke Day 2025 | Press release | PR Newswire | +0.05% | -0.12% | |
| Terumo Interventional Systems Announces Its New OPUSWAVE® Dual Sensor Imaging System and DualView® Imaging Catheter Receive FDA 510(k) Clearance | Press release | PR Newswire | +0.00% | +2.92% | |
| The Blood Center in New Orleans modernizes platelet processing with FDA-cleared automation from Terumo Blood and Cell Technologies | Press release | PR Newswire | — | -0.50% | |
| Terumo Neuro Launches Aneurysm Treatment Alliance in EMEA to Advance Physician Collaboration and Aneurysm Care | Press release | PR Newswire | +0.00% | -2.88% | |
| Terumo Neuro Unveils New SOFIA™ Flow 88 Neurovascular Aspiration Catheter Data from EMEA Demonstrating Strong Performance | Press release | PR Newswire | +0.00% | -2.88% | |
| Terumo to acquire OrganOx Limited, a leading innovator in organ preservation devices, marking strategic entry into the organ transplantation-related sector | Press release | GlobeNewswire | +0.11% | -0.84% | |
| Terumo Neuro Unveils New SOFIA™ 88 Catheter Data Demonstrating Strong Performance Compared to Other Super-Bore Catheters | Press release | PR Newswire | -1.03% | +0.00% | |
| Terumo Health Outcomes Announces Distribution Agreement for Caretaker Medical's VitalStream® Non-Invasive Hemodynamic Monitoring | Press release | PR Newswire | +0.00% | +4.12% | |
| Expanding a Stroke Legacy: Terumo Neuro Announces EMEA Commercial Availability of the SOFIA™ Flow 88 Neurovascular Aspiration Catheter | Press release | PR Newswire | +0.00% | +4.53% | |
| Terumo Interventional Systems Announces Commercial Availability of Its ROADSAVER™ Carotid Stent System | Press release | PR Newswire | +0.10% | +0.10% | |
| Expanding a Stroke Legacy: Terumo Neuro Announces US Commercial Availability of the SOFIA™ 88 Neurovascular Support Catheter | Press release | PR Newswire | +4.17% | +4.37% | |
| Terumo Blood and Cell Technologies Names Patrick Daly as Chief Business Officer | Press release | PR Newswire | -0.48% | -0.59% | |
| Terumo Health Outcomes Now Offers FDA-Cleared Medis QFR® 3.0 Software for Coronary Physiology Assessment in the US | Press release | PR Newswire | +0.08% | -0.43% | |
| Terumo Neuro Receives FDA Approval for Carotid Stent System | Press release | PR Newswire | +7.22% | +3.15% | |
| Terumo Neuro Celebrates 15 Years of the WEB™ Device: A Game-Changing Innovation in Aneurysm Treatment | Press release | PR Newswire | +2.59% | +4.40% | |
| Terumo Neuro Showcases Fully Integrated, Comprehensive Stroke Portfolio at International Stroke Conference Delivering Groundbreaking Innovation from Access to Revascularization | Press release | PR Newswire | +0.00% | +0.16% | |
| Terumo Health Outcomes and Medis Medical Imaging Announce Strategic Partnership to Enhance Cardiovascular Care | Press release | PR Newswire | +0.00% | -0.55% | |
| Terumo Interventional Systems Announces Launch of Its R2P NaviCross Peripheral Support Catheter | Press release | PR Newswire | +0.00% | -0.05% | |
| Patients, Scientists Agree: Automated Red Blood Cell Exchange Enhances Quality of Life in Sickle Cell Disease Patients | Press release | PR Newswire | +0.03% | +0.46% | |
| NAMSA and TERUMO Announce Strategic Outsourcing Partnership | Press release | Business Wire | +0.00% | -1.67% | |
| MicroVention Rebrands to Terumo Neuro – Reflects Expanded Focus and Strategic Growth | Press release | Business Wire | -1.01% | -0.59% | |
| Terumo Establishes Corporate Venture Capital "Terumo Ventures" | Press release | Canada Newswire | +0.00% | +5.81% | |
| MicroVention Announces Release of CLinical EValuation of WEB™ 17 Device in Intracranial Aneurysms (CLEVER): One Year Effectiveness Results for Ruptured and Unruptured Aneurysms | Press release | Business Wire | +0.00% | +0.23% | |
| MicroVention Announces Settlement Against Former Employees for Trade Secret Misappropriation and Breach of Contract Among Other Claims | Press release | Business Wire | +0.00% | +0.75% | |
| MicroVention Announces Clinical Publication of SOFAST: SOFIA™ Aspiration System as First Line Technique in Treating Acute Ischemic Stroke | Press release | Business Wire | +0.00% | +2.95% | |
| MicroVention Announces the Next Evolution in Stent Innovation: MicroVention’s LVIS™ EVO™ Intraluminal Support Device Now Available in the United States | Press release | Business Wire | +0.00% | -1.47% | |
| Terumo Cardiovascular Announces 510(K) Clearance for the CDI OneView™ Monitoring System | Press release | PR Newswire | +0.00% | -0.12% | |
| FDA Clears the Individualized Nomogram for Rika Plasma Donation System | Press release | PR Newswire | +0.00% | -0.05% | |
| Terumo Medical Corporation's New AZUR HydroPack™ Peripheral Coil System Provides a Soft-Packing, Long-Lasting Solution to Embolotherapy | Press release | PR Newswire | +0.00% | -3.23% | |
| MicroVention Celebrates 10-Year Anniversary and Legacy of SOFIA™ Aspiration Catheters; More than 500,000 Procedures Performed Worldwide Across 170 Countries | Press release | Business Wire | +0.47% | +0.34% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the TRUMY section they belong to.
Where else TRUMY is measured.
TRUMY earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Navidea Biopharmaceuticals, Inc. (NAVB) | 43 | +5.93% | 82% |
| POLYDEX PHARMS LTD (POLXF) | 43 | 0.00% | 35% |
| Nova Leap Health Corp (NLH_CDNX) | 42 | 0.00% | 20% |
| Regional Health Properties, Inc. (RHE) | 42 | +1.71% | 61% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is TERUMO CORP UNSP/ADR's median reaction calculated?
Every labeled TRUMY news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 43 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 61% of TRUMY's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does TRUMY's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.